GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx to Participate in Upcoming Investor Conferences.

GeneDx Holdings has grown revenue from $70.5M in Q2 2024 to $123.1M in Q3 2026 and lifted gross margin to roughly 69.9%, which suggests the genetic testing platform has real demand and pricing traction.
Price trend, volume and key moving averages
Trailing total returns as of 11/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 9, 2026 | $0.28+284.3% vs $0.07 | $123M+0.1% vs $123M |
Q3 2026 Aug 3, 2026 | $0.01+105.3% vs -$0.19 | $114M+3.1% vs $111M |
Q2 2026 May 4, 2026 | -$0.28-366.7% vs -$0.06 | $102M-9.1% vs $112M |
Q1 2026 Feb 23, 2026 | $0.14+27.3% vs $0.11 | $121M+0.6% vs $120M |
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx to Participate in Upcoming Investor Conferences.

GeneDx lowered its 2026 exome and genome volume growth target to at least 28% after third-quarter testing volume fell short of expectations. Sales rose 5% to $123.1 million, in line with estimates, but the 32,134 exome and genome results were up 25% against the 29.2% or more the company had promised.

Several stocks are seeing unusual options activity following their latest earnings reports, with Hims & Hers Health Inc (NYSE:HIMS), GeneDx Holdings Corp (NASDAQ:WGS), Groupon Inc (NASDAQ:GRPN), and Digital Turbine Inc (NASDAQ:APPS) all suffering double-digit losses today.

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx Research Demonstrates Medical Actionability of Exome and Genome Sequencing Results in Large Real-World Study of More Than 300,000 Patients.
Benchmark WGS against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for GeneDx Holdings Corp. (WGS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $47.29 | $1.41B | -12.72 | 39.97% | -24.1% | -42.26% | — | |
| $1.82 | $565.3M | -4.32 | 3.89% | -81.31% | -2618.51% | — | |
| $287.47 | $41.17B | -251.44 | 35.9% | -5.66% | -9.18% | — | |
| $74.56 | $3.85B | 31.87 | 13.79% | 25.86% | 34.08% | — | |
| $202.61 | $30.65B | 34.86 | -0.78% | 19.72% | 31.45% | — | |
| $5.75 | $1.53B | -28.54 | 18.96% | -43.56% | -28.22% | — |
GeneDx Holdings Corp. (WGS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
GeneDx Holdings Corp. (WGS) SEC filings — annual & quarterly reports (10-K, 10-Q)
Nov 9, 2026·SEC
Aug 3, 2026·SEC
Jun 23, 2026·SEC
Get notified when WGS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
GeneDx Holdings Corp. (WGS) stock FAQ — growth, dividends, profitability & financials explained
GeneDx Holdings Corp. (WGS) reported $460.8M in revenue over the trailing twelve months. Revenue was $427.5M in fiscal year 2025. That is 138% more than the $179.3M of fiscal year 2020.
GeneDx Holdings Corp. (WGS) grew revenue by 14.6% over the trailing twelve months, compared with the twelve months before.
No. GeneDx Holdings Corp. (WGS) reported a net loss of $111.0M over the trailing twelve months.
GeneDx Holdings Corp. (WGS) had a return on equity (ROE) of -42.3% over the trailing twelve months. A negative ROE means the company lost money over the period.
GeneDx Holdings Corp. (WGS) had negative free cash flow of $101.2M over the trailing twelve months.